Navigation Links
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
Date:5/26/2009

in 50-mg, 75-mg and 100-mg doses. The FDA-approved trade name for tapentadol is NUCYNTA(TM) (pronounced 'new-sinn-tah'), and the U.S. Drug Enforcement Agency has placed tapentadol into Schedule II of the Controlled Substances Act.

Tapentadol binds to mu-opioid receptors and inhibits norepinephrine re-uptake. Although the exact mechanism of action is not known, these two mechanisms, which affect established pain pathways, are thought to be responsible for pain relief with tapentadol. It is also being developed in an extended release formulation for chronic pain.

Study Design

This Phase 3, double-blind, randomized, active- and placebo-controlled, parallel group, multi-center trial of 901 patients with moderate-to-severe pain following bunionectomy studied the safety and efficacy of tapentadol IR for postoperative analgesia. Patients were randomly assigned in a 4:4:4:1 ratio to receive tapentadol IR 50-mg, tapentadol IR 75-mg, oxycodone HCl IR 10-mg, or placebo every four to six hours over a 72-hour period following surgery. The primary efficacy endpoint was the sum of pain intensity difference (SPID) over the first 48 hours of treatment. The secondary endpoints included SPID over the first 12, 24, and 72 hours of treatment, responder rates at 48 hours based on the reduction of pain intensity compared with baseline, and patient overall status using a 7-point patient global impression of change numerical rating scale. The current study differs from the previously completed Phase 3 bunionectomy study in allowing two doses of acetaminophen 1 g in the first 12 hours of the double-blind treatment period. The allowed use of acetaminophen was intended to improve completion rates in the current study.

IMPORTANT SAFETY INFORMATION

Like other drugs with mu-opioid activity, NUCYNTA(TM) is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
2. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
3. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
4. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
5. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
8. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
9. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
10. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
11. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... -- The potential of the pulmonary route ... agents has been receiving undeniable attention with the recent ... The crucial formulation considerations for orally inhaled products together ... role in the efficiency of pulmonary delivery, and great ... formulation techniques and devices in recent years. ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... EDGE, N.J. , May 23, 2013 ... a commercial stage medical device company that develops and ... successful completion of its rights offering.  In addition, the ... March 2011 warrants expired on May 17, 2013. ... of $3.0 million from the rights offering.   A portion ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
(Date:5/24/2013)... commonly used to treat glaucoma may cause droopy eyelids ... according to a new study. The drugs, known ... eye pressure, have already been shown to cause blurred ... said, suggesting that the new findings could lead to ... conservative when prescribing these drugs, the researchers added, particularly ...
(Date:5/24/2013)... of highly respected Alzheimer,s researchers failed to replicate what ... this brain disease when they were published last year ... presented online Feb. 9, 2012, suggested that the drug ... of beta amyloid plaques (Aβ) a pathological hallmark ... According to the authors of the 2012 report, drug ...
(Date:5/24/2013)... New York, New York (PRWEB) May 24, 2013 ... da Vinci lawsuit involving Intuitive Surgical Inc.’s da ... According to court records, a Washington State Court ... not committed negligence in training a surgeon who performed ... several years later. The patient’s family had alleged ...
(Date:5/24/2013)... 2013 Dwell Media LLC ... as Executive Vice President of Digital for Dwell Media. ... represented a large portion of Yahoo's global media business. ... develops a fully-integrated commerce unit to launch in 2014. ... digital content for leading firms in Silicon Valley. Dwell, ...
(Date:5/24/2013)... 24 (HealthDay News) -- People with high levels of ... die of liver disease than those with lower levels, ... cadmium in urine is evidence of long-term exposure to ... and tobacco smoke, the Johns Hopkins researchers explained. ... cadmium directly causes liver disease but instead suggest an ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2
... but often deadly disease that can strike at any time ... and in the past was referred to as a silent ... ovarian cancer that can assist in early detection. Experts at ... of preventive methods, understand the risks and recognize potential warning ...
... that the hormone estrogen may help reverse advanced pulmonary hypertension, ... million individuals in the U.S., mostly women, and can lead ... progressive increase in blood pressure in the main pulmonary artery, ... to the lungs. The rise in pressure impairs heart function ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... increasing rates of drug-resistant tuberculosis, health officials say the disease ... least so far. But, they add, the ease of ... one should think they,re beyond risk. "Drug-resistant TB exists ...
... The demand for transparency through publicly available healthcare data ... and clinical data for research, and for clinical trials data ... a measurable impact on research and policy making. A new ... in Electronic Health Information at the University of Ottawa and ...
... spent glued to their PlayStation 3, Xbox 360 or Nintendo ... perhaps? Improved concentration? Superior driving skills? Over the past ... action video games such as Medal of Honor or Unreal ... in a paper published this week in the journal Frontiers ...
... HealthDay Reporter , WEDNESDAY, Sept. 14 (HealthDay News) ... jumped dramatically worldwide, from about 640,000 in 1980 to more ... Over the same period, the number of cases of ... from that cancer have declined, although in 2010 it still ...
Cached Medicine News:Health News:Early detection is key in the fight against ovarian cancer 2Health News:Early detection is key in the fight against ovarian cancer 3Health News:Estrogen treatment may help reverse severe pulmonary hypertension 2Health News:Estrogen treatment may help reverse severe pulmonary hypertension 3Health News:Officials Tackle Multidrug-Resistant TB in Europe 2Health News:Officials Tackle Multidrug-Resistant TB in Europe 3Health News:New report on creating clinical public use microdata files 2Health News:Put down that Xbox remote: FSU researcher suggests video games may not boost cognition 2Health News:Put down that Xbox remote: FSU researcher suggests video games may not boost cognition 3Health News:Breast Cancer Rates Jump Worldwide, Study Finds 2Health News:Breast Cancer Rates Jump Worldwide, Study Finds 3
... Based on Volks revolutionary MiniQuad, the DynaView ... field view of the retina extending to ... and adult patients. Featuring a minified housing ... DynaView 156 revolutionizes retinopathy of prematurity surgery ...
... MiniQuad XL is recommended for ... entire fundus and in the ... is the ideal lens for ... the operating microscope. It provides ...
... Iridectomy Lens enhances iridectomy procedures by ... (than conventional iridectomy lens designs) with ... on this lens has been increased ... 11.7mm. The MagPlus comes standard with ...
... is an advanced fundus laser lens design ... superior high magnification viewing and treatment of ... computer designed aspheric optics provide improved performance ... Fundus Lens comes standard with LaserWindow® for ...
Medicine Products: